Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies

被引:628
作者
Mahrholdt, H [1 ]
Wagner, A
Judd, RM
Sechtem, U
Kim, RJ
机构
[1] Duke Cardiovasc MR Ctr, Durham, NC 27706 USA
[2] Robert Bosch Krankenhaus, Div Cardiol, D-70376 Stuttgart, Germany
关键词
CMR; cardiomyopathy; MRI; contrast enhancement; delayed enhancement;
D O I
10.1093/eurheartj/ehi258
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-ischaemic cardiomyopathies (NICMs) are chronic, progressive myocardial diseases with distinct patterns of morphological, functional, and electrophysiological changes. In the setting of cardiomyopathy (CM), determining the exact aetiology is important because the aetiology is directly related to treatment and patient survival. Determining the exact aetiology, however, can be difficult using currently available imaging techniques, such as echocardiography, radionuclide imaging or X-ray coronary angiography, since overlap of features between CMs may be encountered. Cardiovascular magnetic resonance (CMR) imaging has recently emerged as a new non-invasive imaging modatity capable of providing high-resolution images of the heart in any desired plane. Delayed contrast enhanced CMR (DE-CMR) can be used for non-invasive tissue characterization and may hold promise in differentiating ischaemic from NICMs, as the typical pattern of hyperenhancement can be classified as 'ischaemic-type' or 'non-ischaemic type' on the basis of pathophysiology of ischaemia. This article reviews the potential of DE-CMR to distinguish between ischaemic and NICM as welt as to differentiate non-ischaemic aetiologies. Rather than simply describing various hyperenhancement patterns that may occur in different disease states, our goal will be (i) to provide an overall imaging approach for the diagnosis of CM and (ii) to demonstrate how this approach is based on the underlying relationships between contrast enhancement and myocardial pathophysiology.
引用
收藏
页码:1461 / 1474
页数:14
相关论文
共 51 条
[1]   HISTO-PATHOLOGICAL TYPES OF CARDIAC FIBROSIS IN MYOCARDIAL-DISEASE [J].
ANDERSON, KR ;
SUTTON, MGS ;
LIE, JT .
JOURNAL OF PATHOLOGY, 1979, 128 (02) :79-&
[2]  
Aretz H T, 1987, Am J Cardiovasc Pathol, V1, P3
[3]  
ARROYO LH, 1999, JAMA-J AM MED ASSOC, V281, P921
[4]   Hypertrophic cardiomyopathy and sudden death in the young: Pathologic evidence of myocardial ischemia [J].
Basso, C ;
Thiene, G ;
Corrado, D ;
Buja, G ;
Melacini, P ;
Nava, A .
HUMAN PATHOLOGY, 2000, 31 (08) :988-998
[5]   Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing β-blocker therapy [J].
Bello, D ;
Shah, DJ ;
Farah, GM ;
Di Luzio, S ;
Parker, M ;
Johnson, MR ;
Cotts, WG ;
Klocke, FJ ;
Bonow, RO ;
Judd, RM ;
Gheorghiade, M ;
Kim, RJ .
CIRCULATION, 2003, 108 (16) :1945-1953
[7]   Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure [J].
Bristow, MR ;
Gilbert, EM ;
Abraham, WT ;
Adams, KF ;
Fowler, MB ;
Hershberger, RE ;
Kubo, SH ;
Narahara, KA ;
Ingersoll, H ;
Krueger, S ;
Young, S ;
Shusterman, N .
CIRCULATION, 1996, 94 (11) :2807-2816
[8]   Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy [J].
Choudhury, L ;
Mahrholdt, H ;
Wagner, A ;
Choi, KM ;
Elliott, MD ;
Klocke, FJ ;
Bonow, RO ;
Judd, RM ;
Kim, RJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (12) :2156-2164
[9]   Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. [J].
Felker, GM ;
Thompson, RE ;
Hare, JM ;
Hruban, RH ;
Clemetson, DE ;
Howard, DL ;
Baughman, KL ;
Kasper, EK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (15) :1077-1084
[10]   A standardized definition of ischemic cardiomyopathy for use in clinical research [J].
Felker, GM ;
Shaw, LK ;
O'Connor, CM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (02) :210-218